{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'T/placebo to 0.1 mg/kg. Subjects with a grade 4 photosensitivity reaction must', 'permanently discontinue Rova-T/placebo.', 'Section 6.1.8.2 Management of Skin Reactions', 'Second paragraph previously read:', 'If clinically consistent with photosensitivity, the AE should be reported as such (using', 'medically accurate and descriptive AE terminology), and managed as described below.', 'Has been changed to read:', 'If clinically consistent with photosensitivity, the AE should be reported as such (using', 'medically accurate and descriptive AE terminology), and managed as described in', 'Table 6.', 'Section 6.1.8.2 Management of Skin Reactions', 'Third paragraph, first sentence previously read:', 'Photo-documentation should be available upon request by the TA MD.', 'Has been changed to read:', 'Photo-documentation of skin toxicity should be available upon request by the TA MD.', 'Section 6.1.8.4 Monitoring and Management of Edema', 'Add: new section title and text', '6.1.8.4', 'Monitoring and Management of Edema', 'The majority of the edema events with rovalpituzumab tesirine have been reported as low', 'grade 1 or 2 (mild or moderate); however, a small number of fatal events of generalized', 'edema have been reported with rovalpituzumab tesirine. Physical exams and monitoring', 'of weight gain and signs or symptoms of fluid retention should be conducted during', 'treatment. Edema events were reported during treatment and may occur up to several', '181']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'months after last Rova-T dose. As a result subjects should be advised of signs and', 'symptoms of fluid retention as well as monitor their weight and contact treating physician', 'if they arise during this time.', 'Consistent with institutional guidelines or standard practice, the use of diuretics with or', 'without albumin may be considered in subjects with clinically significant edema and', 'hypoalbuminemia. The selection and use of diuretics in subjects should be based on', 'individual clinical characteristics and include monitoring of electrolyte status and signs or', 'symptoms of intravascular volume depletion such as hypotension and impaired renal', 'function.', 'Systemic corticosteroids, when initiated promptly, have been reported to be beneficial in', 'some prior cases.', '182']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Reported Term', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Generalized', 'Noted on exam;', 'Interfering with', 'Interferes with', 'Life-', 'edema', '1+ pitting edema', 'instrumental ADLs; oral', 'self care ADL;', 'threatening', '(Anasarca)', 'therapy initiated', 'intravenous', 'consequences', 'therapy indicated;', 'skin breakdown', 'Definition: A disorder characterized by fluid accumulation in the tissues of the body including the skin.', 'Edema trunk', 'Swelling or', 'Readily apparent', 'Gross deviation', 'obscuration of', 'obscuration of anatomic', 'from normal', 'anatomic', 'architecture; obliteration', 'anatomic contour;', 'architecture on', 'of skin folds; readily', 'limiting self care', 'close inspection', 'apparent deviation from', 'ADL', 'normal anatomic contour;', 'limiting instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.', 'Edema limbs', '5 - 10% inter-limb', '> 10 - 30% inter-limb', '> 30% inter-limb', 'discrepancy in', 'discrepancy in volume or', 'discrepancy in', 'volume or', 'circumference at point of', 'volume; gross', 'circumference at', 'greatest visible difference;', 'deviation from', 'point of greatest', 'readily apparent', 'normal anatomic', 'visible difference;', 'obscuration of anatomic', 'contour; limiting', 'swelling or', 'architecture; obliteration', 'self care ADL', 'obscuration of', 'of skin folds; readily', 'anatomic', 'apparent deviation from', 'architecture on', 'normal anatomic contour;', 'close inspection', 'limiting instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the upper or', 'lower extremities', 'Section 6.1.8.5 Pneumonitis', 'Add: new section title and text', '6.1.8.5', 'Pneumonitis', 'Pneumonitis has been infrequently reported with rovalpituzumab tesirine but has resulted', 'in fatal outcomes. Although the causal role of rovalpituzumab tesirine could not be ruled', 'out, the reports of pneumonitis had one or more confounders including underlying', 'pulmonary disease/cancer, prior thoracic radiation, prior cytotoxic chemotherapy or', 'clinical evidence suggestive of an alternative diagnosis including pneumonia.', '183']\n\n###\n\n", "completion": "END"}